Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation.

Wahl, Richard L.; Quint, Leslie E.; Greenough, Robert; Meyer, Charles R.; White, Richard I.; Orringer, Mark B.

doi:10.1148/radiology.191.2.8153308

Cited by 380 publications

(104 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…FDG PET therefore must be considered as a very sensitive technique, but a technique whose specificity is imperfect and must be compensated for by careful selection of patients and rigorous correlation with anatomical images (including image fusion, whenever possible) [49].…”

Section: Biological Characteristics Of 18-fdgmentioning

confidence: 99%

“…These studies must be separated into two groups, Some investigators have used focal techniques and have concentrated on hilar and mediastinal lymph node staging, while others have used whole-body techniques and have evaluated extrathoracic (Table 2) [49,[110][111][112][113][114][115][116][117][118][119]. The reported sensitivity for lymph node staging in non-small cell lung cancer varies from 82% to 100% and the specificity from 73% to 100%.…”

Section: Fig 2 Malignant Solitary Pulmonary Nodule (Adenosquamous Cmentioning

confidence: 99%

See 1 more Smart Citation

Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose

Rigo¹,

Paulus²,

et al. 1996

View full text Add to dashboard Cite

Abstract. Positron emission tomography (PET) is now primarily used in oncological indication owing to the successful application of fluorine-18 fluorodeoxyglucose (FDG) in an increasing number of clinical indications at different stages of diagnosis, and for staging and followup. This review first considers the biological characteristics of FDG and then discusses methodological considerations regarding its use. Clinical indications are considered, and the results achieved in respect of various organs and tumour types are reviewed in depth. The review concludes with a brief consideration of the ways in which clinical PET might be improved.

show abstract

Section: Biological Characteristics Of 18-fdgmentioning

confidence: 99%

Section: Fig 2 Malignant Solitary Pulmonary Nodule (Adenosquamous Cmentioning

confidence: 99%

Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose

Rigo¹,

Paulus²,

et al. 1996

View full text Add to dashboard Cite

show abstract

“…Image fusion became popular in diagnostic imaging with the introduction of positron emission tomography (PET)-CT fusion [16,17], which is now considered a routine application in nuclear medicine. Similarly, in cardiac radiology, image fusion is becoming more important by combining CT information about coronary artery disease and MR information about myocardial perfusion [3,18,19].…”

Section: Discussionmentioning

confidence: 99%

MR/CT image fusion of the spine after spondylodesis: a feasibility study

et al. 2010

View full text Add to dashboard Cite

The objective of this study is to evaluate feasibility, accuracy and time requirements of MR/CT image fusion of the lumbar spine after spondylodesis. Sagittal MR and CT images derived from standard imaging protocols (sagittal T2-weighted MR/sagittal reformatted multi-planar-reformation of the CT) of the lumbar spine with correct (n = 5) and incorrect (n = 5) implant position were fused by two readers (R1, R2) using OsiriX in two sessions placing one (session 1) or two (session 2) reference point(s) on the dorsal tip(s) of the cranial and caudal endplates from the second lumbar to the first sacral vertebra. R1 was an experienced musculoskeletal radiologist; R2 a spine surgeon, both had received a short training on the software tool. Fusion times and fusion accuracy, defined as the largest deviation between MR and CT in the median sagittal plane on the ventral tip of the cranial end plate of the most cranial vertebra visible on the CT, were measured in both sessions. Correct or incorrect implant position was evaluated upon the fused images for all patients by an experienced senior staff musculoskeletal radiologist. Mean fusion time (session 1/session 2; in seconds) was 100.4/95 (R1) and 104.2/119.8 (R2). Mean fusion deviation (session 1/session 2; in mm) was 1.24/2.20 (R1) and 0.79/1.62 (R2). The correct/incorrect implant position was identified correctly in all cases. In conclusion, MR/CT image fusion of the spine with metallic implants is feasible, fast, accurate and easy to implement in daily routine work.

show abstract

“…Because of this very moderate level of accuracy of CT, invasive staging by mediastinoscopy until recently remained the only reliable tool for mediastinal LN staging. The use of FDG-PET as a noninvasive tool for the determination of LN spread has thus been examined in several well-designed prospective studies [27,[57][58][59][60][61][62][63][64][65][66][67][68][69][70][71][72]. FDG-PET proved to be significantly more accurate than CT in locoregional LN staging.…”

Section: Locoregional Lymph Node Stagingmentioning

confidence: 99%

Imaging in lung cancer: positron emission tomography scan

Vansteenkiste¹

2002

Eur Respir J

View full text Add to dashboard Cite

In the past 5 yrs, positron emission tomography (PET), usually used with 18 F-fluoro-2-deoxy-glucose (FDG), has become an important imaging modality in lung cancer patients.Currently, the use of FDG-PET in respiratory oncology is mainly for diagnosis and staging. Standard indications are the evaluation of an indeterminate solitary pulmonary nodule or mass, where FDG-PET has proven to be significantly more accurate than computed tomography (CT) in the distinction between benign and malignant lesions. Several studies have also convincingly demonstrated that locoregional lymph node staging by FDG-PET (in correlation with CT images) is significantly superior to CT, with a negative predictive value equal or even superior to mediastinoscopy. FDG-PET also improves extrathoracic staging, through the detection of lesions missed at conventional imaging or characterization of lesions that remain equivocal on conventional imaging. Many European countries now have or plan reimbursement in these indications. Large-scale randomized studies should now focus on the impact this accurate tumour imaging technique has on treatment outcome and cost-efficacy.Ongoing studies in specialized centres focus on the use of FDG-PET in more advanced clinical applications, such as planning radiotherapy, response evaluation after radiotherapy or (induction) chemotherapy, follow-up and early detection of recurrence, and prognostic information in this in vivo measurement of tumour glucose metabolism.After a short note on the technique used and a summary of the current common indications of diagnosis and staging, this paper will deal mainly with two of the more advanced clinical applications of FDG-PET in locally advanced nonsmall cell lung cancer: radiation treatment planning and assessment of induction chemotherapy.Finally, it should be mentioned that a whole new field of applications of positron emission tomography in molecular biology, using new radiopharmaceutical probes, is under extensive investigation. These techniques are promising for future use in very early response monitoring during chemo-or radiotherapy, in evaluation of novel molecular-targeted lung cancer therapies, or even gene therapy.

show abstract

Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation.

Abstract: FDG PET was more accurate than CT in staging disease in the mediastinum in patients with lung cancer and appears to be the preferred imaging method in this clinical setting.

Cited by 380 publications

References 0 publications

Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose

Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose

MR/CT image fusion of the spine after spondylodesis: a feasibility study

Imaging in lung cancer: positron emission tomography scan

Contact Info

Product

Resources

About